Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Risk and Volatility
Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Unicycive Therapeutics and Siga Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Unicycive Therapeutics and Siga Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 212.56 | -$26.56 million | ($1.75) | -2.97 |
| Siga Technologies | $53.66 million | 4.30 | $23.28 million | ($0.05) | -64.20 |
Siga Technologies has higher revenue and earnings than Unicycive Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Unicycive Therapeutics and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
| Siga Technologies | -5.19% | -1.55% | -1.32% |
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 2.7% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Unicycive Therapeutics beats Siga Technologies on 8 of the 14 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
